Navigation Links
ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability
Date:3/3/2009

In ClearTrial v2.7, the newest version of the award-winning clinical trial software, ClearTrial introduces Portfolio Planning capability which enables clinical development organizations to roll up protocol-level study plans into portfolio-level forecasts in minutes. The software provides instant visibility to monthly budgets, monthly resource demand, and timelines across a program, business unit, therapeutic indication, region, service provider or any other dimension - a capability unique to the industry.

Chicago (PRWEB) March 3, 2009 -- ClearTrial (www.cleartrial.com), a leading provider of clinical trial software for clinical trial operations planning, budgeting, and outsourcing, announced today that it has released version 2.7 of its market-leading ClearTrial clinical trial software, which helps biopharmaceutical companies and clinical research organizations (CROs) accelerate and improve the planning and execution of their clinical trials. Today, 6 of the top 10 biotech companies and many of the largest companies in the industry rely on ClearTrial software to bring quality treatments to market faster, with less cost and effort.

With ClearTrial Portfolio Planning, available in the Enterprise Edition of ClearTrial v2.7, clinical development organizations can now roll up protocol-level study plans into portfolio-level forecasts in minutes, providing instant visibility to monthly budgets, monthly resource demand, and timelines across a program, business unit, therapeutic indication, region, service provider or any other dimension - a capability unique to the industry. And when protocol-level assumptions change, the software automatically updates the portfolio forecast in seconds.

With ClearTrial Portfolio Planning, clinical trial professionals can:

  • Aggregate multiple studies into a program/portfolio view or long-range plan
  • Generate comprehensive monthly budget, resource, and timeline reports
  • Add or remove studies from a portfolio
  • Modify study start dates
  • Adjust study probabilities

"ClearTrial Portfolio Planning gives life sciences companies a lightning-fast and more informed portfolio and program decision-making capability that presents a major competitive advantage, especially in today's economic climate," noted Mike Soenen, Managing Partner of ClearTrial. "The pressure to move faster with fewer resources has never been greater and with Portfolio Planning, ClearTrial is again first in class to answer that challenge."

Key Benefits of ClearTrial Portfolio Planning
For clinical operations, outsourcing, finance, and project/resource management professionals at life sciences organizations, ClearTrial Portfolio Planning offers:

Integrated Roll-up for Increased Accuracy and Speed - The software eliminates errors in the time-consuming re-keying involved with manually rolling up multiple study plans into program- or company-wide forecasts. ClearTrial Portfolio Planning also ensures that planners are using the most current information by automatically updating the portfolio forecast with any changes made to the protocol-level assumptions.

Effortless Cost and Resource Demand Forecasting Across the Organization - Monthly cost and resource demand forecasts enable companies to easily identify areas of heavy FTE utilization, and more proactively hire or contract for additional resources - or modify study start dates to smooth out resource utilization. Planners can instantly see the budget and resource impact of dropping or delaying a study or group of studies, immediately assess the result on hours and fees, by month, of outsourcing all monitoring, and more.

Flexibility to Support Business Objectives and Processes - ClearTrial Portfolio Planning enables the creation of portfolios along any clinical development dimension to:

  • Compare portfolios for multiple long-range planning scenarios
  • Assign probability weighting to in-licensing and out-licensing deals
  • Accurately model later-stage studies that are dependent on early study success for more accurate stage-gate decision-making
  • Assess program-level outsourcing strategies

"With version 2.7, ClearTrial continues to set the standard for clinical software that helps life sciences companies bring new, quality treatments to market more rapidly," Soenen stated. "We're pleased to introduce this much-needed capability to the benefit of the industry."

About ClearTrial®
ClearTrial® is a leading provider of clinical trial software for clinical operations planning, budgeting, and outsourcing. ClearTrial's award-winning software helps pharmaceutical, biotechnology, medical device companies, and CROs expedite the clinical development process without sacrificing quality of results. The company's software products support clinical operations, resource planning, and outsourcing departments with a single solution that promotes speed and consistency, while maintaining flexibility to handle different study requirements. For more information please visit http://www.cleartrial.com.

ClearTrial® and the ClearTrial logo are registered trademarks owned by ClearTrial, LLC, which may be registered in certain jurisdictions. Any other company or product names mentioned in this release are hereby acknowledged as registered trademarks or trademarks of their respective owners.

###

Read the full story at http://www.prweb.com/releases/2009/03/prweb2201104.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. ClearTrial Selected to Lead Industry Panel on Managing Clinical Trial Cash Flow and Accruals at CBI Conference
2. Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimers Disease
3. Genencor Launches Accellerase(R) 1500, Next Step Toward Scale-Up of Cellulosic Ethanol
4. EyeScience Launches Comprehensive Online Resource Devoted to Age-Related Macular Degeneration Education and Prevention
5. Smith & Nephew Launches VISIONAIRE(TM) Patient Matched Technology for Total Knee Replacement
6. CUREXO Technology Corporation Launches Its ROBODOC(R) Surgical System at Upcoming Orthopaedic Conference in Las Vegas
7. BioSpace.com Launches a New Season of Industry Career Fairs
8. Millipore Launches an Interactive Biological Pathway Tool Using GeneGos Manually Curated Pathway Maps
9. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
10. Cephalons New Product Launches Pace Record 2008 Sales
11. BioComp Pharma Launches First Generic Drug for Tindamax(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... ... cells for research and the development of cardiac regeneration therapies. The development ... numbers of cardiomyocytes (hPSC-CMs). Due to varying differentiation efficiencies, further enrichment of ...
(Date:5/23/2017)... ... May 22, 2017 , ... NetDimensions has been ranked as ... Globe™ for Corporate Learning, 2017. , Aragon Research defines Leaders as organizations who ... perform against those strategies. NetDimensions’ ranking as a Leader due to its strengths ...
(Date:5/23/2017)... ... 2017 , ... Vortex Biosciences , provider of circulating tumor cell (CTC) ... cells using Vortex microfluidic technology ” in Nature Precision Oncology on May 8th. ... Carlo and Dr. Matthew Rettig at the University of California, Los Angeles. The publication ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... Works as Vice President of Clinical Operations. She brings years of expertise ... Yaupon Therapeutics. From her professional foundation as a licensed occupational therapist, through a ...
Breaking Biology Technology:
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based and ... 2022", published by MarketsandMarkets, the market is expected to be worth USD 18.98 ... Continue Reading ... ...      ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel visited the ... the DERMALOG stand together with the Japanese Prime Minster Shinzo Abe. ... largest German biometrics company the two government leaders could see the three ... as DERMALOG´s multi-biometrics system.   Continue Reading ... ...
Breaking Biology News(10 mins):